Long-term efficacy and safety of extracorporeal shock wave therapy (Li-ESWT) protocols in the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) patients

References

• Magistro G, Wagenlehner FM, Grabe M, et al. Contemporary management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol. 2016;69(2):286–297. doi: 10.1016/j.eururo.2015.08.061.
   PubMed Web of Science ®Google Scholar
• Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282(3):236–237. doi: 10.1001/jama.282.3.236.
   PubMed Web of Science ®Google Scholar
• Trishch VI, Matskevych VM, Mysak AI, et al. Evaluation of efficacy of extracorporeal shock wave therapy in complex treatment of patients with chronic non-bacterial prostatitis/chronic pelvic pain syndrome. Wiad Lek. 2021;74(8):1834–1838. doi: 10.36740/WLek202108110.
   PubMedGoogle Scholar
• Polackwich AS, Shoskes DA. Chronic prostatitis/chronic pelvic pain syndrome: a review of evaluation and therapy. Prostate Cancer Prostatic Dis. 2016;19(2):132–138. doi: 10.1038/pcan.2016.8.
   PubMed Web of Science ®Google Scholar
• Culha MG, Tuken M, Gonultas S, et al. Frequency of etiological factors among patients with acquired premature ejaculation: prospective, observational, single-center study. Int J Impot Res. 2020;32(3):352–357. doi: 10.1038/s41443-019-0188-x.
   PubMed Web of Science ®Google Scholar
• Tuğcu V, Taşçi AI, Fazlioğlu A, et al. A placebo-controlled comparison of the efficiency of triple- and monotherapy in category III B chronic pelvic pain syndrome (CPPS). Eur Urol. 2007;51(4):1113–1117; discussion 1118. doi: 10.1016/j.eururo.2006.09.036.
   PubMed Web of Science ®Google Scholar
• Schneider MP, Tellenbach M, Mordasini L, et al. Refractory chronic pelvic pain syndrome in men: can transcutaneous electrical nerve stimulation help? BJU Int. 2013;112(2):E159–E163. doi: 10.1111/bju.12005.
   PubMed Web of Science ®Google Scholar
• Chopra S, Satkunasivam R, Aron M. Feasibility of robotic radical prostatectomy for medication refractory chronic prostatitis/chronic pelvic pain syndrome: initial results. Indian J Urol. 2016;32(3):238–241. doi: 10.4103/0970-1591.185105.
   PubMedGoogle Scholar
• Marszalek M, Berger I, Madersbacher S. Low-energy extracorporeal shock wave therapy for chronic pelvic pain syndrome: finally, the magic bullet? Eur Urol. 2009;56(3):425–426. doi: 10.1016/j.eururo.2009.03.075.
   PubMed Web of Science ®Google Scholar
• Guu SJ, Geng JH, Chao IT, et al. Efficacy of low-intensity extracorporeal shock wave therapy on men with chronic pelvic pain syndrome refractory to 3-As therapy. Am J Mens Health. 2018;12(2):441–452. doi: 10.1177/1557988317736585.
   PubMed Web of Science ®Google Scholar
• Zimmermann R, Cumpanas A, Miclea F, et al. Extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome in males: a randomised, double-blind, placebo-controlled study. Eur Urol. 2009;56(3):418–424. doi: 10.1016/j.eururo.2009.03.043.
   PubMed Web of Science ®Google Scholar
• Kim KS, Choi YS, Bae WJ, et al. Efficacy of low-intensity extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome IIIb: a prospective-randomized, double-blind, placebo-controlled study. World J Mens Health. 2022;40(3):473–480. doi: 10.5534/wjmh.210010.
   PubMedGoogle Scholar
• Li G, Man L. Low-intensity extracorporeal shock wave therapy for male chronic pelvic pain syndrome: a systematic review and meta-analysis. Transl Androl Urol. 2021;10(3):1202–1211. doi: 10.21037/tau-20-1423.
   PubMed Web of Science ®Google Scholar
• Litwin MS, McNaughton-Collins M, Fowler FJ Jr, et al. The National Institutes of Health Chronic Prostatitis Symptom Index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol. 1999;162(2):369–375. doi: 10.1016/s0022-5347(05)68562-x.
   PubMed Web of Science ®Google Scholar
• Coşkun A, Can U, Tarhan F, et al. Reliability and validity of the National Institutes of Health Chronic Prostatitis Symptom Index questionnaire in the Turkish population. Turk J Med Sci. 2021;51(2):501–507. doi: 10.3906/sag-2001-231.
   PubMed Web of Science ®Google Scholar
• Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549–1557; discussion 1564. doi: 10.1016/s0022-5347(17)36966-5.
   PubMed Web of Science ®Google Scholar
• Rosen RC, Riley A, Wagner G, et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822–830. doi: 10.1016/s0090-4295(97)00238-0.
   PubMed Web of Science ®Google Scholar
• Turunc T, Deveci S, Güvel S, et al. The assessment of Turkish validation with 5 question version of International Index of Erectile Function (IIEF-5). Turk Uroloji Derg. 2007;33:45–49.
   Google Scholar
• d’Agostino MC, Craig K, Tibalt E, et al. Shock wave as biological therapeutic tool: from mechanical stimulation to recovery and healing, through mechanotransduction. Int J Surg. 2015;24(Pt B):147–153. doi: 10.1016/j.ijsu.2015.11.030.
   PubMedGoogle Scholar
• Xin ZC, Xu YD, Lin G, et al. Recruiting endogenous stem cells: a novel therapeutic approach for erectile dysfunction. Asian J Androl. 2016;18(1):10–15. doi: 10.4103/1008-682X.150040.
   PubMed Web of Science ®Google Scholar
• Li J, Li Y, Cao D, et al. The association between histological prostatitis and benign prostatic hyperplasia: a single-center retrospective study. Aging Male. 2022;25(1):88–93.
   PubMedGoogle Scholar
• Sahin A, Kutluhan MA, Yildirim C, et al. Results of purified micronized flavonoid fraction in the treatment of categorized type III chronic pelvic pain syndrome: a randomized controlled trial. Aging Male. 2020;23(5):1103–1108. doi: 10.1080/13685538.2019.1678581.
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen J, Jiang Q, et al. Resolvin D1 attenuates inflammation and pelvic pain associated with EAP by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO-1 pathway. J Inflamm Res. 2023;16:3365–3379. doi: 10.2147/JIR.S408111.
   PubMed Web of Science ®Google Scholar
• Diri MA, Gul M. Bipolar prostate thermotherapy for the improvement of chronic prostatitis symptoms and ejaculation problems. Aging Male. 2020;23(5):1004–1008. doi: 10.1080/13685538.2019.1650906.
   PubMed Web of Science ®Google Scholar
• Pattabiraman G, Engel G, Osborn CV, et al. Efficacy of targeted mast cell inhibition therapy in chronic prostatitis/chronic pelvic pain syndrome. Urology. 2023:S0090-4295(23)00586-1. doi: 10.1016/j.urology.2023.05.049.
   Web of Science ®Google Scholar
• Wang HJ, Cheng JH, Chuang YC. Potential applications of low-energy shock waves in functional urology. Int J Urol. 2017;24(8):573–581. doi: 10.1111/iju.13403.
   PubMed Web of Science ®Google Scholar
• Fischer S, Mueller W, Schulte M, et al. Multiple extracorporeal shock wave therapy degrades capsular fibrosis after insertion of silicone implants. Ultrasound Med Biol. 2015;41(3):781–789. doi: 10.1016/j.ultrasmedbio.2014.10.018.
   PubMed Web of Science ®Google Scholar
• Sokmen D, Comez YI. Efficacy and safety of extracorporeal shock wave therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome and acquired premature ejaculation patients. Urol Int. 2023 [cited 2023 August 23]; [5 p.].
   PubMed Web of Science ®Google Scholar
• Fode M, Russo GI, Verze P. Therapeutic areas of Li-ESWT in sexual medicine other than erectile dysfunction. Int J Impot Res. 2019;31(3):223–230. doi: 10.1038/s41443-019-0114-2.
   PubMed Web of Science ®Google Scholar
• Pajovic B, Radojevic N, Dimitrovski A, et al. Comparison of the efficiency of combined extracorporeal shock-wave therapy and triple therapy versus triple therapy itself in category III B chronic pelvic pain syndrome (CPPS). Aging Male. 2016;19(3):202–207. doi: 10.1080/13685538.2016.1197899.
   PubMed Web of Science ®Google Scholar
• Guu SJ, Liu CC, Juan YS, et al. The 12-month follow-up of the low-intensity extracorporeal shockwave therapy in the treatment of patients with chronic pelvic pain syndrome refractory to 3-As medications. Aging Male. 2020;23(5):793–800. doi: 10.1080/13685538.2019.1597341.
   PubMed Web of Science ®Google Scholar
• Sokolakis I, Hatzichristodoulou G. Clinical studies on low intensity extracorporeal shockwave therapy for erectile dysfunction: a systematic review and meta-analysis of randomised controlled trials. Int J Impot Res. 2019;31(3):177–194. doi: 10.1038/s41443-019-0117-z.
   PubMed Web of Science ®Google Scholar
• Wu WL, Bamodu OA, Wang YH, et al. Extracorporeal shockwave therapy (ESWT) alleviates pain, enhances erectile function and improves quality of life in patients with chronic prostatitis/chronic pelvic pain syndrome. J Clin Med. 2021;10(16):3602.
   Web of Science ®Google Scholar
• Scroppo FI, Pezzoni F, Gaeta F, et al. Li-ESWT improves hemodynamic parameters thus suggesting neoangiogenesis in patients with vascular erectile dysfunction. Int J Impot Res. 2022;34(3):237–242. doi: 10.1038/s41443-021-00411-0.
   PubMed Web of Science ®Google Scholar
• Yao H, Wang X, Liu H, et al. Systematic review and meta-analysis of 16 randomized controlled trials of clinical outcomes of low-intensity extracorporeal shock wave therapy in treating erectile dysfunction. Am J Mens Health. 2022;16(2):15579883221087532. doi: 10.1177/15579883221087532.
   Web of Science ®Google Scholar